SCHEMBL3009736

SCHEMBL3009736

COc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4Cl)CC3)n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.47
HSD17B10 Q99714 2/20 0.47
RECQL P46063 2/20 0.47
USP2 O75604 1/20 0.47
TRPV4 Q9HBA0 1/20 0.45
ALDH1A1 P00352 7/20 0.44
LMNA P02545 4/20 0.44
HPGD P15428 1/20 0.44
PKM P14618 1/20 0.43
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
MAPK1 P28482 3/20 0.42
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 1/20 0.41
POLB P06746 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009996 0.93 MAPT (0.47) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3002069 0.92 TRPV4 (0.43) MAPTHSD17B10RECQLUSP2TRPV4
SCHEMBL3015552 0.91 ALDH1A1 (0.49) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3001188 0.91 MAPT (0.54) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3015539 0.91 MAPT (0.46) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3014108 0.91 MAPT (0.49) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3014572 0.90 ACLY (0.46) MAPTHSD17B10RECQLUSP2TRPV4
SCHEMBL3005343 0.89 MAPT (0.57) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3011747 0.89 MAPT (0.47) MAPTHSD17B10RECQLUSP2ALDH1A1
SCHEMBL3018039 0.89 MAPT (0.48) MAPTHSD17B10RECQLUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.